Topikal leverans av biologiska läkemedel för hudföryngring
| Reference number | |
| Coordinator | Kungliga Tekniska Högskolan - KTH Skolan för elektroteknik och datavetenskap |
| Funding from Vinnova | SEK 1 000 000 |
| Project duration | November 2024 - October 2025 |
| Status | Completed |
| Venture | Preparation projects for international application within health |
| Call | Towards deeper collaboration with UK and USA partners within Health and Life Science |
Important results from the project
We have successfully completed a pilot study where we topically delivered lipid nanoparticles with mRNA encoding protein expression and verified uptake into skin cells. This has been an important milestone for the project where we are now moving forward with more verifications and also investigating partially new forms of therapy that shown to be viable, e.g. in gene editing. We continue the commercial dialogue with our US partner and support them in verifying our technology in human models.
Expected long term effects
The results could enable completely new forms of therapy in dermatology. New biological drugs currently have to be injected, but we have shown that these can also be used topically in the form of a cream that is applied to the skin. The technology also forms part of the initial networking for VR excellence clusters in future RNA therapies.
Approach and implementation
The project has gone well. A new technology has been tested and verified. It has led to deeper and new collaborations that drive development forward and create growth and value for the parties involved. There are legal challenges in collaborating between a Swedish university and an American company, but these challenges have been managed within the project.